Natalie Dales - Academia.edu (original) (raw)
Related Authors
University of Maryland School of Medicine
Beckman Research Institute of City of Hope
Uploads
Papers by Natalie Dales
Syn Commun, 1998
Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... &... more Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... 'Departnzent of' Chemistry and School of Pharmacy, University of Wisconsin-Madison, 425 North Charter Street, Madison, WI 53 706. hBristol-Myers Squibb Pharmaceutical Research Institute, ...
ChemInform, 1999
Synthesis of (3R)-Amino-(2S)-hydroxy Amino Acids for Inhibition of Methionine Aminopeptidase-1.
CHIMIA International Journal for Chemistry
ABSTRACT
Synthetic Communications, 1998
Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... &... more Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... 'Departnzent of' Chemistry and School of Pharmacy, University of Wisconsin-Madison, 425 North Charter Street, Madison, WI 53 706. hBristol-Myers Squibb Pharmaceutical Research Institute, ...
Journal of the American Chemical Society, 2002
Journal of Investigative Dermatology, 2013
Journal of Biological Chemistry, 2004
The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral memb... more The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH ؉ E zincbinding consensus sequence. ACE2 has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2-and 3.0-Å resolution, respectively. Comparison of these structures revealed a large inhibitor-dependent hinge-bending movement of one catalytic subdomain relative to the other (ϳ16°) that brings important residues into position for catalysis. The potent inhibitor
Journal of Biological Chemistry, 2004
Bioorganic & Medicinal Chemistry Letters, 2014
We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2... more We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The mouse liver microsomal SCD1 in vitro potency for 19 was improved by more than 240-fold compared to the original HTS hit. Furthermore, 19 demonstrated a dose-dependent reduction of plasma desaturation index with an ED50 of 6.3 mg/kg. Compound 19 demonstrated high liver to plasma and liver to eyelid exposures, indicating preferential liver distribution. The preliminary toxicology study with compound 19 did not demonstrate adverse effects related to SCD1 inhibition, suggesting a wide safety margin with respect to other known SCD1 inhibitors with wider distribution profiles.
Syn Commun, 1998
Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... &... more Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... 'Departnzent of' Chemistry and School of Pharmacy, University of Wisconsin-Madison, 425 North Charter Street, Madison, WI 53 706. hBristol-Myers Squibb Pharmaceutical Research Institute, ...
ChemInform, 1999
Synthesis of (3R)-Amino-(2S)-hydroxy Amino Acids for Inhibition of Methionine Aminopeptidase-1.
CHIMIA International Journal for Chemistry
ABSTRACT
Synthetic Communications, 1998
Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... &... more Stacy J. Keding,a Natalie A. Dales: Sejin Lim,a Danielle Beaulieu: Daniel H. Richa* ... 'Departnzent of' Chemistry and School of Pharmacy, University of Wisconsin-Madison, 425 North Charter Street, Madison, WI 53 706. hBristol-Myers Squibb Pharmaceutical Research Institute, ...
Journal of the American Chemical Society, 2002
Journal of Investigative Dermatology, 2013
Journal of Biological Chemistry, 2004
The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral memb... more The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH ؉ E zincbinding consensus sequence. ACE2 has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2-and 3.0-Å resolution, respectively. Comparison of these structures revealed a large inhibitor-dependent hinge-bending movement of one catalytic subdomain relative to the other (ϳ16°) that brings important residues into position for catalysis. The potent inhibitor
Journal of Biological Chemistry, 2004
Bioorganic & Medicinal Chemistry Letters, 2014
We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2... more We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The mouse liver microsomal SCD1 in vitro potency for 19 was improved by more than 240-fold compared to the original HTS hit. Furthermore, 19 demonstrated a dose-dependent reduction of plasma desaturation index with an ED50 of 6.3 mg/kg. Compound 19 demonstrated high liver to plasma and liver to eyelid exposures, indicating preferential liver distribution. The preliminary toxicology study with compound 19 did not demonstrate adverse effects related to SCD1 inhibition, suggesting a wide safety margin with respect to other known SCD1 inhibitors with wider distribution profiles.